METHODS: We utilized patient data prospectively collected from a "Phase 2 trial of neoadjuvant axitinib in patients with locally advanced non-metastatic clear cell renal carcinoma" (NCT01263769). Patients received axitinib for up to 12 weeks prior to surgical extirpation. Mass spectrometry-based proteome analysis was performed on urine samples collected both prior to treatment and at week 19 (6-7 weeks post-operatively). Linear regression models were used to model the relationship between the percent decrease in tumor diameter and urinary protein values. Cox proportional hazards models were used to identify associations with pre-operative protein levels and response to axitinib and survival outcomes.
INTRODUCTION AND OBJECTIVES: Renal cell carcinoma (RCC) is the most common type of kidney malignancy. At present, we do not have a simple, minimally invasive and economic diagnostic method for RCC. Circulating cell free DNA (cfDNA) can be found in biological fluids and it has been proposed as biomarker for several cancers other than RCC. Our aim was to explore the diagnostic and prognostic value of the assessment of cfDNA in urine for RCC.
METHODS: We prospectively recruited 23 patients with RCC, of whom 12 had clear cell RCC (ccRCC), 9 had papillary RCC (pRCC) and 2 had chromophobe RCC (chRCC). We collected three samples from each individual: a first morning urine sample at recruitment (before surgery), another 3 months after surgery and another 1 year after surgery. In addition, we recruited 23 healthy controls with normal renal and bladder ultrasound, matched for age and sex with patients, from whom we obtained a first morning urine sample. We evaluated and optimized the performance of 5 DNA isolation kits for urine. Next, we isolated cfDNA from all urine samples and quantified by real-time quantitative PCR the expression level of cfDNA of six genes previously studied in other cancer types: AR, ERBB2, c-MYC, BCAS1, ACTB and STOX1. A standard curve was prepared with DNA isolated from the renal cell line HEK 293 and was used as reference for quantification. Statistical analysis was performed using R (v3.2.3).
RESULTS: The QIAampÒ Viral RNA Mini Kit (Qiagen), with several modifications, provided the best yield and purity in the cfDNA isolation from urine samples. We observed a significant increase in the expression level of c-MYC in patients with ccRCC compared to controls (P[0.024). The presence of DNA fragments of c-MYC in urine is associated with an increased risk of ccRCC (OR[ 2.82; ). Moreover, the expression level of c-MYC increased with severity in ccRCC patients: in stage 2 compared to stage 1 (OR[ 3.41; 1.32-9.07; P[0.012) and in stage 3 compared to stage 1 (OR[ 2.59; 0.99-6.8; P[0.053). In chRCC we observed a decrease in the expression level of STOX1 in the last sample (1 year after surgery), compared to the sample prior to surgery (P[0.012). This decrease in DNA fragments of STOX1 in urine is associated with a decrease in the risk of chRCC (OR[ 0.02; , what may indicate the remission of the tumour after surgery.
CONCLUSIONS: The expression level of c-MYC may be a novel and non-invasive diagnostic biomarker for ccRCC, the most frequent subtype of renal cancer. Additionally, the expression level of STOX1 may be a prognostic marker for chRCC. These promising results need to be confirmed in a larger population, for which we are currently recruiting more patients and controls in order to replicate and validate them. 
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Julia Oto, M a Jos e Solmoirago, Jos e Vicente S anchez-Gonz alez*, Javier P erez-Ardavin, Emma Plana, David Herv as, Alvaro Fern andez-Pardo, Marina Yelo, C esar D. Vera-Donoso, Manuel Martínez-Sarmiento, Francisco España, Silvia Navarro, Pilar Medina, Valencia, Spain INTRODUCTION AND OBJECTIVES: Renal cell carcinoma (RCC) is the most common type of urinary malignancy. Clear cell RCC (ccRCC) is the predominant RCC subtype, accounting for 70-80% of RCC. microRNAs (miRs) are small non-coding RNAs that regulate protein expression. miRs have been proved to regulate cancer progression and represent potential diagnostic and prognostic biomarkers. Our aim was to find a profile of miRs in urine capable of distinguishing between ccRCC patients and controls.
METHODS: Two clinical groups were recruited: 54 RCC patients from whom three urine samples were obtained (t0[ before surgery, t1[3 months after surgery, t2[one year after surgery) and 58 healthy volunteers (controls) with an ultrasound scan to rule out urological tumours from whom one urine sample was obtained. The expression level of 179 miRs was studied in urine of 16 selected ccRCC patients (at t0 and t1) and 16 controls, age and gender matched, using the Serum/plasma Focus microRNA PCR Panel V4 (Exiqon). An endogenous reference miR was selected as that with the highest stability using RefFinder software. Normalization of miR expression was conducted with the DDCt method, and subsequently results were also normalized with the level of creatinine. Statistical analysis was performed using R (v3.2.3).
RESULTS: The most stable miR was miR-20a-5p and therefore we used it as endogenous reference. We adjusted an Elastic Net logistic regression model for the diagnosis of ccRCC using the miR expression levels in urine of patients at t0 and controls. This model included 3 miRs: miR-200a-3p, miR-34a-5p and miR-365a-3p. Moreover, with the Wilcoxon test we identified 5 dysregulated miRs comparing the miR expression level of patients at t0 and controls: miR-200a-3p, let-7d-5p, miR-205-5p, miR-34a-5p and miR-365a-3p. Furthermore, we identified 5 dysregulated miRs comparing patients at t0 and t1: let-7d-5p, miR-152-3p, miR-30c-5p, miR-362-3p and miR30e-3p. These last 5 miRs could be involved in the prognosis of ccRCC.
CONCLUSIONS: We have obtained a urine profile of 3 miRs with potential diagnostic value for ccRCC. We also identified 5 dysregulated miRs in patients comparing before and after surgery, and other
